Updates are available Correction dated 2023-05-19
Click to view Correction: https://doi.org/10.1186/s40644-023-00548-9
-
Authors
Sjöholm, Therese https://orcid.org/0000-0003-3072-749X
Korenyushkin, Alexander
Gammelgård, Gustav
Sarén, Tina
Lövgren, Tanja
Loskog, Angelica
Essand, Magnus
Kullberg, Joel
Enblad, Gunilla
Ahlström, Håkan
-
Funding
Funding for this research was provided by:
Cancerfonden (20 1303PjF, 19 0184Pj)
Vetenskapsrådet (2019-01326, 2019-01721)
Uppsala University
- License Information
-
More Information
Article History
Received: 17 June 2022
Accepted: 17 December 2022
First Online: 27 December 2022
Change Date: 19 May 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s40644-023-00548-9
Declarations
:
: This study was approved by the Regional Ethics Review Board (Dnr 2017/053) and all patients gave their informed written consent to participate.
: Our research contains no personal data.
: JK and HA are co-founders of Antaros Medical AB. GE is a scientific advisor for Elicera Therapeutics AB and XNK Therapeutics AB and a member of the advisory board for Gilead. ME is co-founder and chief scientific officer for Elicera Therapeutics. AL is the CEO of Lokon Pharma AB, chairwoman of Repos Pharma AB and Vivolux AB as well as board member of Lokon Pharma AB, Tanea Medical AB and Aros Bioscience AB. She is alternate board member of Nexttobe AB and Almo Alo AB. Further, she holds a research grant from Lokon Pharma AB.
